
Multiple myeloma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the PBS subsidised for lenalidomide
and pomalidomide for patients with multiple myeloma (MM).

Multiple myeloma and listing dates

Multiple myeloma (MM) is a type of blood cancer.

Listing dates:

-   Lenalidomide - 1 November 2009
-   Pomalidomide - 1 August 2015

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, calculation
sheets, contact details, item codes, restriction, and PBS and Services
Australia websites.

Related links

Written Authority Required Drugs

Processing Written Authority Required Listings

Process telephone Authority approval application

Manage work items in Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

                                   

-   Services Australia ABN 90 794 605 008 
